Contact us

Media

Media Contacts & Information

This information is intended for journalists located in the UK only. Click here for general enquiries.

Contact information for UK journalists:
Email: enquiries@taurx.com

Filter:

Sort by:

TauRx welcomes summit with UK’s top patient advocacy groups

Journal of Prevention of Alzheimer’s Disease publishes results from confirmatory TauRx study into efficacy of potential oral treatment

18 February 2026

TauRx donates £2,500 to baby loss charity Sands

26 January 2026

Journal of Prevention of Alzheimer’s Disease publishes trial results showing HMTM potentially offers accessible oral treatment option for patients with early Alzheimer’s disease

TauRx submits UK marketing authorisation application for HMTM as a treatment for Alzheimer’s disease

Two year sustained cognitive benefits of Hydromethylthionine Mesylate (HMTM) indicated by TauRx’s LUCIDITY trial

1 2 3 4 ... 6

Further reading

Company history

For decades, Professor Claude Wischik, co-founder and CEO of TauRx, has led a scientific research team dedicated to finding an effective treatment for neurodegenerative diseases.

Doctor or nurse caregiver with senior couple at home or nursing home

Clinical trials

TauRx recently completed its latest Phase III clinical trials in Alzheimer’s disease and in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD).

Environmental, Social and Governance at TauRx

Maintaining integrity, accountability and transparency in our pursuit of life-changing treatments